Tag Archive for: #Synaffix

Optimum’s Year-End Review  

2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year.   M&A & deals Synaffix continued to build momentum – Lonza acquired the […]

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

New deal builds on encouraging preliminary clinical data from the Phase 1 study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021 The expanded collaboration to provide Innovent with access to additional targets and further proprietary Synaffix linker-payloads for the development of additional innovative ADCs  Synaffix will be eligible to […]

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies  SOTIO to develop up to three next generation bioconjugates  Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs  AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage […]

ABL Bio Taps into Synaffix ADC Technology

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with […]

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, […]